Further research conducted for the annual 2013 Cell Line Development & Engineering conference in Vienna next February, showed major developments in cell culture systems have given biotech's and pharmaceutical companies more flexibility to scale up cells to a high manufacturing quality.The production of high-performing cell lines have been enabled by cell engineering tools and this has only been possible through improvements in cell culture media.

For best accommodation of these new developments, Informa Life Sciences' have expanded the programme to cover the latest in cell line development strategies and improvements in cell culture systems. Alison Porter, Head of Cell Line Development in the Mammalian Cell Culture group at Fujifilm Diosynth Biotechnologies (FFDB) clarifies how "For first in human studies with cell line construction on the critical path, it is vital to have optimised the early stages of cell line development. This can improve the future success of a biotherapeutic, both in terms of having the 'best' cell line and meeting increasingly tight timelines."

Further feedback from over 50 industry professionals and academics also highlight additional trends such as high throughput screening of cell lines, Quality by Design applications, cell line development strategies for novel products, analytical tools for product evaluation and bioinformatics applications.

Informa's annual 2013 Cell Line Development & Engineering conference has been designed to address topics essential to improve product development and quality. Susanna Benaim Conference Producer at Informa Life Sciences explains "The event uncovers the essentials in micro-scale system application, CHO genome sequencing, cell line engineering and targeted integration. The conference brings together leading experts from protein engineering, cell biology, cell line development and bioprocess, from both the pharmaceutical industry and academia. Any company specialising in this area is encouraged not to miss out."